Plus   Neg

Illumina Tanks 13% As Q2 Results Miss Estimates

Shares of Illumina Inc. (ILMN) slipped more than 13% in after-hours trading after the biotech company reported a second-quarter results that fell short of Wall Street expectations, hurt largely pandemic-related disruptions.

Second-quarter net income was $47 million or $0.32 per share, compared to $296 million or $1.99 per share last year.

Adjusted income for the quarter was $92 million or $0.62 per share, compared to $200 million or $1.35 per share last year.

Revenues for the quarter dropped 25% to $633 million from $838 million last year.

Analysts polled by Thomson Reuters expected earnings of $0.67 per share on revenues of $679.56 million for the quarter.

"As expected, the second quarter was significantly impacted by pandemic-related disruption in our customers' operations and was particularly challenging for many of our research customers who remain closed or operating at limited scale," said Francis deSouza, President and CEO. "It is clear that the role of genomics in infectious disease will continue to grow through and beyond this pandemic."

ILMN closed Thursday's trading at $399.33, down $1.41 or 0.35%, on the Nasdaq. The stock further dropped $52.45 or 13.13% in the after-hour trading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Data giant S&P Global Inc. has agreed to acquire information and analytics company IHS Markit Ltd. in an all-stock deal, the two companies said Monday. The deal values IHS Markit at an enterprise value of $44 billion, including $4.8 billion of net debt. Shares of IHS Markit are gaining almost 6 percent following the news. The deal is the biggest in 2020. Moderna, Inc. (MRNA) said it will apply for an Emergency Use approval of its Covid vaccine as the latest study showed that the vaccine candidate is 94.1% effective to prevent Covid-19. The company said there have been no serious safety concerns identified. The company will file for an Emergency... Vegpro International is recalling Fresh Attitude baby spinach citing potential to be contaminated with Salmonella, according to the U.S. Food and Drug Administration. The recall involves Fresh Attitude baby spinach of 5oz with best before dates of December 4 & 5; and 11oz with best before date of December 4.
Follow RTT